Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Mike Dybbs
AddedFeb 15, 2024
UpdatedMay 31, 2026
Mike Dybbs

Mike Dybbs

Board Member, Sutro Biopharma

CrunchbaseThe Org

Mike Dybbs's Career

Sutro Biopharma
Sutro Biopharma

South San Francisco, CA, US

Board Member· Board
Fluent BioSciences
Fluent BioSciences

Watertown, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Mike Dybbs's Career

Sutro Biopharma
Sutro Biopharma
Public$561.6M2782003South San Francisco, CA, US
Board Member· Board

Leadership at Sutro Biopharma

Jon WiggintonJon WiggintonBoard Member
David H MackDavid H MackBoard Member
Joseph LobackiJoseph LobackiBoard Member
William NewellWilliam NewellBoard Member
Daniel PetreeDaniel PetreeBoard Member
John G. FreundJohn G. FreundBoard Member

Similar to Sutro Biopharma

Sorrento TherapeuticsSorrento TherapeuticsSan Diego, CA, USTherapeuticsest. 2006Sorrento TherapeuticsSan Diego, CA, US · est. 2006

Sorrento Therapeutics: A San Diego-based biopharmaceutical firm specializing in therapeutic antibodies for various diseases.

Public · $264.4M949
Immune-Onc TherapeuticsImmune-Onc TherapeuticsPalo Alto, CA, USCancer Treatmentest. 2016Immune-Onc TherapeuticsPalo Alto, CA, US · est. 2016

California-based Immune-Onc Therapeutics develops therapeutic antibodies for cancer treatment.

Public · $140.1M35
SunnyBay BioTechSunnyBay BioTechFremont, CA, USCancer Treatmentest. 2018SunnyBay BioTechFremont, CA, US · est. 2018

SunnyBay BioTech: Personalized cancer treatment through innovative antibody therapies, based in Fremont, CA.

Seed · $2.2M50
Bolt BiotherapeuticsBolt BiotherapeuticsRedwood City, CA, USCancer Therapeuticsest. 2015Bolt BiotherapeuticsRedwood City, CA, US · est. 2015

Bolt Biotherapeutics: A biotech firm developing immune-stimulating cancer therapeutics, traded publicly in the US.

Public · $198.5M91
Fluent BioSciences
Fluent BioSciences
Series B$22.9M192018Watertown, MA, US
Board Member· Board

Leadership at Fluent BioSciences

Wouter MeulemanWouter MeulemanBoard Member
Tim HarknessTim HarknessBoard Member
William (Bill) HyunWilliam (Bill) HyunBoard Member
Gary ZweigerGary ZweigerCo-Founder
Sepehr KianiSepehr KianiCo-Founder
Adam AbateAdam AbateBoard Member

Similar to Fluent BioSciences

Parse BiosciencesParse BiosciencesSeattle, WA, USData Analysis, Sequencingest. 2018Parse BiosciencesSeattle, WA, US · est. 2018

Seattle-based Parse Biosciences offers scalable single-cell sequencing platforms to accelerate scientific research.

Series C · $100M119
FluidigmFluidigmSouth San Francisco, CA, USBiotechnologyest. 1999FluidigmSouth San Francisco, CA, US · est. 1999

Standard BioTools Inc., based in South San Francisco, accelerates life sciences research with essential, standardized technologies.

Public615
FlexomicsFlexomicsBoston, MA, USScreening Platformest. 2019FlexomicsBoston, MA, US · est. 2019

Flexomics: A high-throughput screening platform bridging genomic and functional analysis.

Seed · $2M4
10x Genomics10x GenomicsPleasanton, CA, USGene Sequencingest. 201210x GenomicsPleasanton, CA, US · est. 2012

10x Genomics: A leading American biotech firm, innovating in gene sequencing since 2012.

Public · $242.6M448

Mike Dybbs's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · Kakao

People Similar to Mike Dybbs

Brian DawsonBrian DawsonBoard Member · Full Cycle BioplasticsRavi RaoRavi RaoFounder · TRex BioAdam AbateAdam AbateCo-Founder · Mission BioOliver HeimesOliver HeimesInvestor · PublicBryan SchreierBryan SchreierBoard Member · Thanx